CN111297761A - Whitening composition and preparation method and application thereof - Google Patents
Whitening composition and preparation method and application thereof Download PDFInfo
- Publication number
- CN111297761A CN111297761A CN202010287184.XA CN202010287184A CN111297761A CN 111297761 A CN111297761 A CN 111297761A CN 202010287184 A CN202010287184 A CN 202010287184A CN 111297761 A CN111297761 A CN 111297761A
- Authority
- CN
- China
- Prior art keywords
- parts
- weight
- extract
- composition
- whitening
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 80
- 230000002087 whitening effect Effects 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 244000153955 Reynoutria sachalinensis Species 0.000 claims abstract description 21
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 claims abstract description 21
- 229940116257 pepper extract Drugs 0.000 claims abstract description 19
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims abstract description 16
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 48
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 39
- 239000004359 castor oil Substances 0.000 claims description 27
- 235000019438 castor oil Nutrition 0.000 claims description 27
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 27
- 239000006071 cream Substances 0.000 claims description 25
- 239000011259 mixed solution Substances 0.000 claims description 24
- 239000003921 oil Substances 0.000 claims description 22
- 229960003966 nicotinamide Drugs 0.000 claims description 21
- 235000005152 nicotinamide Nutrition 0.000 claims description 21
- 239000011570 nicotinamide Substances 0.000 claims description 21
- 238000003756 stirring Methods 0.000 claims description 20
- 238000002156 mixing Methods 0.000 claims description 19
- 239000002994 raw material Substances 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- BTFJIXJJCSYFAL-UHFFFAOYSA-N icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 claims description 12
- -1 arachidyl alcohol glucoside Chemical class 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 7
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims description 6
- 229940035437 1,3-propanediol Drugs 0.000 claims description 6
- 240000001341 Reynoutria japonica Species 0.000 claims description 6
- 235000018167 Reynoutria japonica Nutrition 0.000 claims description 6
- 238000004945 emulsification Methods 0.000 claims description 6
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- 229920002125 Sokalan® Polymers 0.000 claims description 4
- FSEJJKIPRNUIFL-UHFFFAOYSA-N [2,2-bis(hydroxymethyl)-3-octadecanoyloxypropyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)(CO)COC(=O)CCCCCCCCCCCCCCCCC FSEJJKIPRNUIFL-UHFFFAOYSA-N 0.000 claims description 4
- 229960001631 carbomer Drugs 0.000 claims description 4
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 4
- 229960000735 docosanol Drugs 0.000 claims description 4
- 229930182478 glucoside Natural products 0.000 claims description 4
- 239000000230 xanthan gum Substances 0.000 claims description 4
- 229920001285 xanthan gum Polymers 0.000 claims description 4
- 229940082509 xanthan gum Drugs 0.000 claims description 4
- 235000010493 xanthan gum Nutrition 0.000 claims description 4
- DGSZGZSCHSQXFV-UHFFFAOYSA-N 2,3-bis(2-ethylhexanoyloxy)propyl 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(OC(=O)C(CC)CCCC)COC(=O)C(CC)CCCC DGSZGZSCHSQXFV-UHFFFAOYSA-N 0.000 claims description 3
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 229940113120 dipropylene glycol Drugs 0.000 claims description 3
- 229960005150 glycerol Drugs 0.000 claims description 3
- 238000000265 homogenisation Methods 0.000 claims description 3
- 229920001296 polysiloxane Polymers 0.000 claims description 3
- 238000005086 pumping Methods 0.000 claims description 3
- 235000020744 piper nigrum extract Nutrition 0.000 claims 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 18
- 210000004369 blood Anatomy 0.000 abstract description 18
- 238000002474 experimental method Methods 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 13
- 239000000126 substance Substances 0.000 abstract description 5
- 238000009472 formulation Methods 0.000 abstract description 2
- 239000004519 grease Substances 0.000 abstract description 2
- 239000002085 irritant Substances 0.000 abstract 1
- 231100000021 irritant Toxicity 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 46
- 230000000052 comparative effect Effects 0.000 description 37
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 18
- 239000000523 sample Substances 0.000 description 17
- 238000002835 absorbance Methods 0.000 description 15
- 230000028327 secretion Effects 0.000 description 11
- 239000002884 skin cream Substances 0.000 description 9
- 238000005303 weighing Methods 0.000 description 9
- 206010067484 Adverse reaction Diseases 0.000 description 8
- 230000006838 adverse reaction Effects 0.000 description 8
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 7
- 230000006872 improvement Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 4
- 229960004889 salicylic acid Drugs 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000002000 scavenging effect Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- GLDQAMYCGOIJDV-UHFFFAOYSA-N 2,3-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC(O)=C1O GLDQAMYCGOIJDV-UHFFFAOYSA-N 0.000 description 2
- PETRWTHZSKVLRE-UHFFFAOYSA-N 2-Methoxy-4-methylphenol Chemical compound COC1=CC(C)=CC=C1O PETRWTHZSKVLRE-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 230000002292 Radical scavenging effect Effects 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000036564 melanin content Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
- 239000001054 red pigment Substances 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 229940082044 2,3-dihydroxybenzoic acid Drugs 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 206010048245 Yellow skin Diseases 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940079877 pyrogallol Drugs 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000036632 reaction speed Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cosmetics (AREA)
Abstract
The invention relates to a whitening composition and a preparation method and application thereof, belonging to the field of daily chemicals. The invention provides a whitening composition, which comprises 1-10 parts by weight of nicotinamide, 0.01-5 parts by weight of giant knotweed extract and 0.01-0.2 part by weight of pepper extract. Experiments prove that the whitening composition has the effects of obviously removing free radicals, improving red blood streak, improving skin color and balancing grease while whitening the skin. The patch experiment proves that the whitening composition is safe and non-irritant, can be widely applied to skin care products of various formulations, and has wide application prospect.
Description
Technical Field
The invention belongs to the field of daily chemicals, and particularly relates to a whitening composition and a preparation method and application thereof.
Background
The safety and efficacy of cosmetics are issues of intense interest to consumers and skin care product developers. At present, a plurality of whitening methods exist, and if the skin problems are rapidly and effectively improved in a short time and the face appearance is improved, scientific beautifying and skin care products are needed.
Most of the whitening products on the market take nicotinamide and VC as main whitening agents. Niacinamide is a water-soluble vitamin and is a member of the vitamin B group. Nicotinamide can inhibit the transfer of melanin, and make skin slowly whiten and more bright. The high-content nicotinamide product has a certain sensitization rate. Meanwhile, melanin produced by the skin has a protective effect on the skin, and excessive inhibition of the production or formation of melanin may have an adverse effect on the skin. For example, the "chalking event by creosol" in Japan is the chalking phenomenon caused by severe destruction of skin melanin after the skin care agent is used. In addition, the other main whitening component VC is easy to discolor and unstable.
The realization of low whitening efficiency through a single approach is one of the problems of the conventional whitening products. Therefore, the development of safe and efficient skin whitening compositions is a problem to be solved in the art.
Disclosure of Invention
The skin-care product takes the nicotinamide as a main whitening agent, is compounded with the plant components of the giant knotweed extract and the pepper extract, and synergistically achieves the skin-care effects of removing free radicals, improving red blood streak, balancing skin color and balancing grease. According to the invention, the plant components such as the giant knotweed extract and the pepper extract are compounded with the nicotinamide, so that the problem of sensitization risk caused by large whitening amount of the nicotinamide is solved, the product safety is improved, the components are synergistic, and the problems of single whitening way and unobvious effect are solved.
In order to solve the problems, the invention adopts the following technical scheme:
the invention provides a whitening composition, which comprises the following raw materials in parts by weight: 1-10 parts of nicotinamide, 0.01-5 parts of giant knotweed extract and 0.01-0.2 part of pepper extract.
According to the invention, the nicotinamide is used in an amount of 1 to 10 parts by weight, and may be, for example, 1, 1.1, 1.5, 2, 2.2, 2.3, 2.4, 2.5, 2.8, 3, 3.1, 3.2, 3.5, 3.8, 4, 4.5, 5, 5.5, 5.8, 6, 6.4, 6.5, 7, 7.4, 7.6, 7.8, 8, 8.8, 9, 9.5, 10 parts by weight, and also values between the aforementioned values.
According to the invention, the polygonum cuspidatum extract is used in an amount of 0.01-5 parts by weight, such as 0.01, 0.02, 0.03, 0.05, 0.1, 0.2, 0.3, 0.6, 0.8, 0.9, 1, 1.1, 1.5, 2, 2.2, 2.3, 2.4, 2.5, 2.8, 3, 3.1, 3.2, 3.5, 3.8, 4, 4.5, 5 parts by weight, and values in between.
According to the invention, the pepper extract is used in an amount of 0.01-0.2 parts by weight, which may be, for example, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.08, 0.09, 0.1, 0.15, 0.2 parts by weight, and values in between.
According to some embodiments of the invention, the composition comprises the following raw materials in parts by weight: 2-6 parts of nicotinamide, 0.1-4 parts of giant knotweed extract and 0.1-0.2 part of pepper extract.
According to some embodiments of the invention, the composition further comprises 1, 3-propanediol.
According to some embodiments of the invention, the composition further comprises PEG-40 hydrogenated castor oil.
According to some further embodiments of the present invention, the composition comprises the following raw materials in parts by weight: 1-10 parts of nicotinamide, 0.01-5 parts of giant knotweed extract, 0.01-0.2 part of pepper extract, 0.01-5 parts of 1, 3-propylene glycol and 0.02-0.5 part of PEG-40 hydrogenated castor oil.
According to the invention, the 1, 3-propanediol is used in an amount of 0.01 to 5 parts by weight, and may be, for example, 0.01, 0.05, 0.1, 0.2, 0.3, 0.5, 0.6, 0.8, 0.9, 1, 1.1, 1.5, 1.8, 2, 2.2, 2.3, 2.4, 2.5, 2.8, 3, 3.1, 3.2, 3.5, 3.8, 4, 4.5, 5 parts by weight, and also values in between the above-mentioned values.
According to the invention, the PEG-40 hydrogenated castor oil is used in an amount of 0.02 to 0.5 parts by weight, and may be, for example, 0.02, 0.03, 0.05, 0.06, 0.1, 0.15, 0.2, 0.25, 0.3, 0.33, 0.35, 0.4, 0.45, 0.47, 0.48, 0.5 parts by weight, and points between the above values.
According to some preferred embodiments of the present invention, the composition comprises 2-6 parts by weight of nicotinamide, 0.1-4 parts by weight of giant knotweed rhizome extract, 0.1-0.2 part by weight of pepper extract, 0.25-5 parts by weight of 1, 3-propanediol and 0.2-0.4 part by weight of PEG-40 hydrogenated castor oil.
In a second aspect of the present invention, there is provided a method for preparing the whitening composition of the first aspect.
According to some embodiments of the invention, the method of preparing comprises the steps of:
(1) mixing fructus Piperis extract with 1, 3-propylene glycol and PEG-40 hydrogenated castor oil, and dissolving to obtain mixed solution;
(2) adding nicotinamide and giant knotweed rhizome extract into the mixed solution obtained in the step (1), and uniformly stirring.
According to the present invention, the whitening composition is prepared at normal temperature.
In a third aspect of the present invention, there is provided a whitening composition according to the first or second aspect of the present invention for use in a skin care product.
According to the invention, the whitening composition can be applied to various formulations of skin care products such as cream, emulsion, facial mask, gel, water aqua, eye cream and the like, and a proper amount of the whitening composition can be added according to the formula and efficacy requirements.
According to the present invention, the suggested addition amount of the whitening composition in the skin care product is 0.5 wt% to 20wt%, preferably 3 wt% to 10wt%
According to some embodiments of the invention, the skin care product is a cream.
According to some embodiments of the invention, the cream comprises the following raw materials in parts by weight:
according to the invention, the cream can be prepared by a method comprising the following steps:
step 1: adding water, xanthan gum, dipropylene glycol, glycerol, carbomer and EDTA disodium into an emulsification tank, heating to 80-85 deg.C, mixing and stirring;
step 2: adding arachidyl alcohol/behenyl alcohol/arachidyl alcohol glucoside, glycerol tri (ethyl hexanoate), pentaerythritol distearate, and cyclopenta dimethyl silicone into an oil phase tank, heating to 80-85 deg.C, mixing, and stirring;
and step 3: pumping the oil phase in the oil phase tank into an emulsification tank, starting homogenization at the rotation speed of 2500-.
And 4, step 4: cooling to 45-60 deg.C, and adding sodium hydroxide;
and 5: adding the composition of the invention and stirring uniformly.
According to the skin care composition, the skin care composition is formed by compounding the nicotinamide with the plant source polygonum cuspidatum extract and the plant source pepper extract, so that the problems of poor whitening effect and safety possibly caused by the independent use of the nicotinamide are solved, the effects of removing free radicals, removing red blood streaks and controlling oil can be achieved while whitening through the compounding and synergistic effect of various components, and the skin care composition has a wide application prospect in skin care products.
Description of the drawings:
FIG. 1 is a graph showing the radical scavenging effect of example 4 and comparative examples 1 to 5;
FIG. 2 is a chart of the results of the VISIA test of skin color after the subject uses the sample of example 5;
FIG. 3 is a chart of the results of the VISIA test of red blood streak status after a subject has tried a sample of example 5;
FIG. 4 is a chart of the results of the VISIA test of skin color after the subject uses the sample of example 6;
FIG. 5 is a chart of the results of the VISIA test of red blood streak status after the subject has tried the sample of example 6;
FIG. 6 is a chart of the results of the VISIA test of skin color after the subject uses the sample of example 7;
FIG. 7 is a chart of the results of the VISIA test of red blood streak status after a subject has tried a sample from example 7;
FIG. 8 is a chart of the results of the VISIA test of skin color after the subject uses the sample of example 8;
FIG. 9 is a chart of the results of the VISIA test of red blood streak status after a subject has tried a sample from example 8;
FIG. 10 is a chart of the results of the VISIA test of skin color after the subject tried the comparative example 6 sample;
FIG. 11 is a chart showing the results of the VISIA test on red blood streak following the trial of comparative example 6 by a subject;
FIG. 12 is a chart of the results of the VISIA test of skin color after the subject uses the comparative example 8 sample;
FIG. 13 is a chart of the VISIA test results of red blood streak following the trial of comparative example 8 by a subject;
FIG. 14 is a chart of the results of the VISIA test of skin color after the subject uses the comparative example 9 sample;
FIG. 15 is a chart of the VISIA test results of red blood streak following the trial of comparative example 9 by a subject;
FIG. 16 is a chart of the results of the VISIA test of skin color after the subject uses the comparative example 10 sample;
FIG. 17 is a chart of the VISIA test results of red blood streak following the trial of comparative example 10 by a subject;
FIG. 18 is a chart showing the results of the VISIA test on oil and fat secretion by a subject after sampling the sample of example 8;
FIG. 19 is a VISIA test result chart of the oil secretion of the blank control sample after the test of the subject.
The specific implementation mode is as follows:
the present invention will be described in detail with reference to the following embodiments, which will become more apparent by describing the embodiments and processes of the present invention. It should be understood by those skilled in the art that the detailed description is only a part of the examples, but not all examples, and is intended to illustrate the invention and not to limit the scope of the invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention. The examples were carried out under the conventional conditions, unless otherwise specified. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
Table main raw material and source
Example 1
Weighing the following raw materials in parts by weight:
1 part by weight of nicotinamide, 5 parts by weight of giant knotweed extract, 0.01 part by weight of pepper extract, 0.01 part by weight of 1, 3-propylene glycol and 0.02 part by weight of PEG-40 hydrogenated castor oil;
mixing the above fructus Piperis extract with 1, 3-propylene glycol and PEG-40 hydrogenated castor oil, and dissolving to obtain mixed solution;
adding nicotinamide and giant knotweed rhizome extract into the mixed solution, and uniformly stirring to obtain the whitening composition A.
Example 2
Weighing the following raw materials in parts by weight:
10 parts of nicotinamide, 0.01 part of giant knotweed rhizome extract, 0.2 part of pepper extract, 5 parts of 1, 3-propylene glycol and 0.4 part of PEG-40 hydrogenated castor oil.
Mixing the above fructus Piperis extract with 1, 3-propylene glycol and PEG-40 hydrogenated castor oil, and dissolving to obtain mixed solution;
and adding the nicotinamide and the polygonum cuspidatum extract into the obtained mixed solution, and uniformly stirring to obtain the whitening composition B.
Example 3
Weighing the following raw materials in parts by weight:
3 parts of nicotinamide, 3 parts of giant knotweed rhizome extract, 0.1 part of pepper extract, 2.5 parts of 1, 3-propylene glycol and 0.2 part of PEG-40 hydrogenated castor oil,
mixing the above fructus Piperis extract with 1, 3-propylene glycol and PEG-40 hydrogenated castor oil, and dissolving to obtain mixed solution;
adding nicotinamide and giant knotweed rhizome extract into the mixed solution, and uniformly stirring to obtain the whitening composition C.
Example 4
Weighing the following raw materials in parts by weight:
6 parts of nicotinamide, 5 parts of giant knotweed rhizome extract, 0.2 part of pepper extract, 5 parts of 1, 3-propylene glycol, 0.4 part of PEG-40 hydrogenated castor oil,
mixing the above fructus Piperis extract with 1, 3-propylene glycol and PEG-40 hydrogenated castor oil, and dissolving to obtain mixed solution;
and adding the nicotinamide and the polygonum cuspidatum extract into the obtained mixed solution, and uniformly stirring to obtain the whitening composition D.
Comparative example 1
Weighing the following raw materials in parts by weight:
2 parts of nicotinamide, 9 parts of giant knotweed rhizome extract, 0.2 part of pepper extract, 5 parts of 1, 3-propylene glycol, 0.4 part of PEG-40 hydrogenated castor oil,
mixing the above fructus Piperis extract with 1, 3-propylene glycol and PEG-40 hydrogenated castor oil, and dissolving to obtain mixed solution;
adding nicotinamide and rhizoma Polygoni Cuspidati extract into the mixed solution, and stirring to obtain skin care composition.
Comparative example 2
Weighing the following raw materials in parts by weight:
3 parts of nicotinamide, 8 parts of giant knotweed rhizome extract, 0.2 part of pepper extract, 5 parts of 1, 3-propylene glycol, 0.4 part of PEG-40 hydrogenated castor oil,
mixing the above fructus Piperis extract with 1, 3-propylene glycol and PEG-40 hydrogenated castor oil, and dissolving to obtain mixed solution;
adding nicotinamide and rhizoma Polygoni Cuspidati extract into the mixed solution, and stirring to obtain skin care composition.
Comparative example 3
Weighing the following raw materials in parts by weight:
6 parts of nicotinamide, 5 parts of pseudo-ginseng extract, 0.2 part of pepper extract, 5 parts of 1, 3-propylene glycol, 0.4 part of PEG-40 hydrogenated castor oil,
mixing the above fructus Piperis extract with 1, 3-propylene glycol and PEG-40 hydrogenated castor oil, and dissolving to obtain mixed solution;
adding nicotinamide and Notoginseng radix extract into the mixed solution, and stirring to obtain skin care composition.
Comparative example 4
Weighing the following raw materials in parts by weight:
6.0 parts of nicotinamide, 5.2 parts of giant knotweed extract, 5 parts of 1, 3-propylene glycol, 0.4 part of PEG-40 hydrogenated castor oil,
mixing the above fructus Piperis extract with 1, 3-propylene glycol and PEG-40 hydrogenated castor oil, and dissolving to obtain mixed solution;
adding nicotinamide and rhizoma Polygoni Cuspidati extract into the mixed solution, and stirring to obtain skin care composition.
Comparative example 5
Weighing the following raw materials in parts by weight:
VC ethyl ether 0.2 weight parts, giant knotweed rhizome extract 8.2 weight parts, pepper extract 0.3 weight parts, 1, 3-propylene glycol 7.5 weight parts, PEG-40 hydrogenated castor oil 0.6 weight parts,
mixing the above fructus Piperis extract with 1, 3-propylene glycol and PEG-40 hydrogenated castor oil, and dissolving to obtain mixed solution;
adding VC ethyl ether and rhizoma Polygoni Cuspidati extract into the mixed solution, and stirring to obtain skin care composition.
Efficacy evaluation test
Experiment for eliminating free radicals in vitro
1. Experimental methods
(1) DPPH free radical (DPPH) scavenging experiments
DPPH is a very stable nitrogen-centered radical, is very stable in organic solvents, is purple in color, has a characteristic absorption peak at 517nm, and when it encounters a radical scavenger, the lone electron of DPPH is paired, resulting in a lighter color and a lower absorbance at the maximum absorption wavelength. Therefore, the effect of removing DPPH can be evaluated by measuring the change in absorbance.
20mg of DPPH (Sigma Co.) was weighed out accurately, and the volume was adjusted to a 250ml volumetric flask using absolute ethanol to obtain a 20mmol/L DPPH solution, and the compositions prepared in example 4 and comparative example were diluted with distilled water to obtain test solutions having different concentrations, respectively. Respectively taking 2ml of test solution with different concentrations and 2ml of 20mmol/L DPPH, uniformly mixing, reacting for 30min, measuring the change of absorbance at the wavelength of 517nm, replacing a contrast solvent with absolute ethyl alcohol, and calculating the inhibition rate according to the following formula.
Inhibition (%) = [1- (Ai-Aj)/Ac ] × 100.
In the formula, Ai is the absorbance of a mixed solution consisting of 2ml of DPPH solution and 2ml of test solutions with different concentrations; aj is the absorbance of a mixed solution consisting of 2ml of test solutions with different concentrations and 2ml of absolute ethyl alcohol; ac was the absorbance of a mixture of 2ml of DPPH solution and 2ml of absolute ethanol.
(2) Hydroxy radical (. OH) scavenging experiments
The hydroxyl free radical is the most active free radical in active oxygen, can almost react with any biomacromolecule in living cells, has extremely high reaction speed, and is the free radical which has the greatest harm to organisms. The clearance rate of the hydroxyl radical is determined by measuring the product obtained by salicylic acid capturing the hydroxyl radical, and if a substance with the function of clearing the hydroxyl radical is added into the reaction system, the absorbance value of the reaction liquid can be reduced. The amount of hydroxyl radicals and the ability of the substance to be determined to scavenge hydroxyl radicals can therefore be described spectrophotometrically. The specific experimental process is as follows:
the compositions prepared in the above examples and comparative examples were diluted 50-fold. Hydroxyl radicals are generated by the Fenton reaction, OH oxidizes salicylic acid to generate 2, 3-dihydroxybenzoic acid with characteristic absorption at 510nm, and the OH clearance is determined by measuring the product obtained by capturing OH with salicylic acid. 3ml of 2mmol/L FeSO4 and 3ml of 1mmol/LH2O2 are added into a 25ml colorimetric tube, the mixture is shaken up, then 3ml of 6mmol/L salicylic acid is added, the mixture is shaken up, the mixture is taken out after being heated in a water bath at 37 ℃ for 15min, and the absorbance A0 is measured. Then adding the above composition with concentration of 2% 0.2ml, 0.4ml, 0.6ml, 0.8ml and 1.0ml respectively, then adding distilled water 0.8ml, 0.6ml, 0.4ml, 0.2ml and 0ml respectively, shaking, heating in water bath for 15min, taking out and measuring absorbance Ax. In order to eliminate the decrease of absorbance value of the system caused by adding 1.0ml of the composition and distilled water, the same method is adopted, the absorbance value A00 is measured after keeping the temperature for 15min, then 1ml of distilled water is added, the absorbance Axx is measured after shaking up, and the decrease of A is A00-Axx.
The composition has the following clearance rate to OH: OH clearance (%) =100(a 0-Ax-a decrease)/a 0.
(3) Superoxide anion radical scavenging experiment
Taking 4.5ml of 0.05mol/L Tris-HCl buffer solution with pH 8.2, placing the solution in a water bath at 25 ℃ for preheating for 20min, respectively adding 1ml of the compositions prepared in the above examples and comparative examples and 0.4ml of 25mmol/L pyrogallol solution, uniformly mixing, reacting in the water bath at 25 ℃ for 5min, adding 1.0ml of 8mol/L HCl to terminate the reaction, taking the Tris-HCl buffer solution as a reference, measuring absorbance at 299nm, and calculating the clearance rate. Blank controls replaced the sample with 1ml of deionized water and three replicates for each treatment.
Formula for calculating clearance: superoxide anion radical clearance (%) =100(a1-a2)/a1, wherein a1 is the average absorbance of the blank and a2 is the average absorbance of the whitening composition.
2. The results of the experiment are shown in FIG. 1.
The results shown in the figure demonstrate that the examples of the present invention have a certain scavenging capacity for DPPH, hydroxyl radicals and superoxide anion radicals. The inventors repeated the above experiments with other examples to arrive at the same conclusion.
Example 5 preparation of skin cream
Raw materials and proportion:
the preparation method comprises the following steps:
step 1: adding water, xanthan gum, dipropylene glycol, glycerol, carbomer and EDTA disodium into an emulsification tank, heating to 80-85 ℃, and mixing and stirring uniformly;
step 2: adding arachidyl alcohol/behenyl alcohol/arachidyl alcohol glucoside, glycerol tri (ethyl hexanoate), pentaerythritol distearate, and cyclopenta dimethyl silicone into an oil phase tank, heating to 80-85 deg.C, mixing, and stirring;
and step 3: pumping the oil phase in the oil phase tank into an emulsification tank, starting homogenization at the rotation speed of 2500-.
And 4, step 4: cooling to 45-60 ℃, and adding sodium hydroxide for neutralization;
and 5: adding the whitening composition, stirring, and discharging.
Example 6 skin cream preparation
Example 6 cream composition a skin care composition was prepared using example 2, the rest being the same as in example 5.
Example 7 skin cream preparation
Example 7 cream composition a skin care composition was prepared using example 3, the rest being the same as in example 5.
Example 8 skin cream preparation
Example 8 cream composition a skin care composition was prepared using example 4, the rest being the same as in example 5.
Comparative example 6 preparation of skin cream
Comparative example 6 cream composition a skin care composition was prepared using comparative example 1, the rest being the same as in example 5.
Comparative example 7 skin cream preparation
Comparative example 7 cream composition a skin care composition was prepared using comparative example 2, the rest being the same as in example 5.
Comparative example 8 skin cream preparation
Comparative example 8 cream composition a skin care composition was prepared using comparative example 3, the rest being the same as in example 5.
Comparative example 9 preparation of skin cream
Comparative example 9 cream composition a skin care composition was prepared using comparative example 4, the rest being the same as in example 5.
Comparative example 10 skin cream preparation
Comparative example 10 cream composition a skin care composition was prepared using comparative example 5, the rest being the same as in example 5.
Evaluation experiment:
first, patch test
30 eligible subjects were selected for testing and informed consent was filled out.
Selecting qualified spot test materials. Putting the tested object into a spot tester, wherein the dosage is about 0.020 g to 0.025 g; where # 0 is a blank control and no sample is present in the plaque tester.
The spot test device with the tested object is applied to the back or the curved side of the forearm of the tested object by using a non-irritating adhesive tape, and is lightly pressed by the palm to be uniformly applied to the skin for 24 hours. And (5) removing the tested substance spot tester for 30min, and observing skin reaction after the indentation disappears. If the result is negative, the result is observed once more after 24 h and 48 h of the patch test respectively, and the reflection result is recorded.
0.5 hour observation of the surface despeckle tester
24-hour observation result of surface despeckle tester
According to the result of the spot sticking test, after 0.5 hour of a spot removal tester, 1 case of 1-grade adverse reaction appears in the No. 2 group, 2 cases of 1-grade adverse reaction appears in the No. 3 group, 2 cases of 1-grade adverse reaction appears in the No. 4 group, 1 case of 1-grade adverse reaction appears in the No. 5 group, 1 case of 1-grade adverse reaction appears in the No. 7 group, 1 case of 1-grade adverse reaction appears in the No. 8 group, and 4 cases of 1-grade adverse reaction appears in the No. 9 group; the adverse reactions of each group disappeared after 24 hours of removal of the plaque tester.
According to the results, the cream sample is evaluated and tested to have no adverse reaction on human skin.
Second, red melanin, skin color, red blood streak and oil secretion test
The test is carried out by adopting a single-center, random, double-blind and self-face left-right contrast method, and 68 subjects with dark and yellow skin color are screened for the test. The subject needs to use different tested whitening creams on the left face and the right face respectively in the morning and at the evening within 6 weeks, and the dosage is based on the actual dosage required for applying the whitening creams on the face. VISIA-CR, facial image capture, and MX18 instrumental measurements were performed 3 times before and at weeks 2 and 6 after the start of the test. Before each test, a subject needs to clean the face with clear water and then sits in a room with constant temperature and humidity for 30min, the face cannot be wiped with paper, and the test is carried out after the face is naturally dried; analyzing the improvement condition of the facial erythema and melanin of the subjects through the measurement result of the MX18 instrument; and analyzing the complexion condition and the improvement condition of the red blood streak before and after the test of the whitening cream by using a VISIA-CR skin test result graph.
1. Melanin content MI value
The experimental method comprises the following steps: the melanin content MI values were measured 3 times in the cheek regions of the subjects at weeks 0, 2 and 6, respectively, and averaged.
The apparatus used was: mexameter MX18
And (3) testing period: 6 weeks
The test results are given in the following table:
3. EI value of red pigment content
The experimental method comprises the following steps: at weeks 0, 2 and 6, 3 measurements of the EI value of the red pigment content were made in the cheek regions of the subjects, and averaged.
The apparatus used was: mexameter MX18
The test results are given in the following table:
the results show that the embodiment of the invention has improved content of skin melanin and haematochrome, and particularly, the embodiment 8 has more obvious improvement on the content of skin melanin and haematochrome; comparative example 7 did not significantly improve red and melanin.
Skin tone and redness testing
Experimental methods
VISIA-CR was used to observe the skin color and red blood streak improvement in subjects at 0 week 2 week 6 week.
The apparatus used was: VISIA-CR skin tester
Introduction of corresponding light sources:
skin color condition: standard Natural light 2
Red blood streak: red Areas Red region
And (3) testing period: 6 weeks
Results of the experiment
The experimental results of examples 5-8, comparative example 6, and comparative example 8-10 VISIA are shown in the attached figures 2-17.
As shown in the attached figures 2-17, the cream of examples 5-8 has certain effect on improving skin color and red blood streak after 6 weeks.
The VISIA picture results show that the examples of the invention have certain improvement effect on the skin color condition and the red blood streak of the subjects, wherein the effect of the example 8 is better, and the overall improvement effect of the comparative example is not good enough.
Third, oil secretion test
In addition, the inventor also unexpectedly finds that the cream has a certain inhibiting effect on skin oil secretion, so that 30 subjects with relatively strong skin oil secretion are screened out and divided into 2 groups, and 15 persons in each group; the test samples were used face-wide using a single-center, randomized, double-blind, placebo-controlled approach. One group used the example 8 sample and the other group used a blank sample (same as example 8 except that the whitening composition of the present invention was not added). The medicine is used once in the morning and at night every day, and the dosage is based on the actual dosage required for applying the medicine on the face. VISIA-CR was taken 3 times before the start of the test and at weeks 2 and 6 after the start of the test. Before each test, a subject needs to clean the face with clear water, sits still in a room with constant temperature and humidity for 30min, cannot wipe the face with paper, and shoots the face with a VISIA-CR skin tester after naturally drying; the oil secretion of the subjects before and after the whitening cream was applied was analyzed by a VISIA-CR skin test result chart.
The apparatus used was: VISIA-CR skin tester
Introduction of corresponding light sources:
oil secretion: porphyrin light
And (3) testing period: 6 weeks
Results of the experiment
Example 8, blank control sample VISIA experimental results are shown in fig. 18 and 19.
As shown in FIGS. 18 and 19, the cream of example 8 was used for 6 weeks, and then it was found to be effective in improving the secretion of skin oil.
As can be seen from the results of VISIA pictures, example 8 of the present invention has a certain effect of improving the secretion of oil in the subject, whereas comparative example 11 has a poor effect of improving the secretion of oil.
In conclusion, the whitening composition has the advantages that the ingredients are synergistic, the whitening effect is good, the effects of controlling oil, removing red blood streaks and improving skin color are good, and the whitening composition has a good application value in the field of skin care products.
Claims (10)
1. A whitening composition comprises the following raw materials in parts by weight: 1-10 parts of nicotinamide, 0.01-5 parts of giant knotweed extract and 0.01-0.2 part of pepper extract.
2. The composition of claim 1, wherein the composition comprises the following raw materials in parts by weight: 2-6 parts of nicotinamide, 0.1-4 parts of giant knotweed extract and 0.1-0.2 part of pepper extract.
3. The composition of claim 1 or 2, wherein the composition further comprises 1, 3-propanediol and/or PEG-40 hydrogenated castor oil.
4. The composition of claim 3, wherein the composition comprises about 1-10 parts by weight of niacinamide, about 0.01-5 parts by weight of Polygonum cuspidatum extract, about 0.01-0.2 parts by weight of Piper nigrum extract, about 0.01-5 parts by weight of 1, 3-propanediol, and about 0.02-0.5 parts by weight of PEG-40 hydrogenated castor oil.
5. The composition of claim 4, wherein the composition comprises about 2 to about 6 parts by weight of niacinamide, about 0.1 to about 4 parts by weight of Polygonum cuspidatum extract, about 0.1 to about 0.2 parts by weight of Piper nigrum extract, about 0.25 to about 5 parts by weight of 1, 3-propanediol, and about 0.2 to about 0.4 parts by weight of PEG-40 hydrogenated castor oil.
6. A method for preparing the whitening composition of any one of claims 1 to 5, comprising the steps of:
(1) mixing fructus Piperis extract with 1, 3-propylene glycol and PEG-40 hydrogenated castor oil, and dissolving to obtain mixed solution;
(2) adding nicotinamide and giant knotweed rhizome extract into the mixed solution obtained in the step (1), and uniformly stirring.
7. Use of the whitening composition of any one of claims 1 to 5 or the whitening composition prepared by the preparation method of claim 6 in skin care products.
8. The use of claim 7 wherein the skin care product comprises a cream, lotion, aqua, mask, eye cream, gel.
9. The use of claim 8, wherein the cream comprises the following raw materials in parts by weight:
0.5-20 wt% of whitening composition, 1-10 wt% of dipropylene glycol, 1-10 wt% of glycerol, 0.01-0.8wt% of carbomer, 0.01-0.1 wt% of disodium EDTA, 0.1-5 wt% of arachidyl alcohol/behenyl alcohol/arachidyl alcohol glucoside, 1-5wt% of triglyceride, 0.1-2 wt% of pentaerythritol distearate, 1-5wt% of cyclopentadimethylsiloxane, 0.02-2 wt% of sodium hydroxide and 0.01-0.2 wt% of xanthan gum.
10. Use according to claim 9, characterized in that the cream is prepared by a preparation process comprising the following steps:
step 1: adding water, xanthan gum, dipropylene glycol, glycerol, carbomer and EDTA disodium into an emulsification tank, heating to 80-85 deg.C, mixing and stirring;
step 2: adding arachidyl alcohol/behenyl alcohol/arachidyl alcohol glucoside, glycerol tri (ethyl hexanoate), pentaerythritol distearate, and cyclopenta dimethyl silicone into an oil phase tank, heating to 80-85 deg.C, mixing, and stirring;
and step 3: pumping the oil phase in the oil phase tank into an emulsification tank, starting homogenization at the rotation speed of 2500-;
and 4, step 4: cooling to 45-60 deg.C, and adding sodium hydroxide;
and 5: adding the whitening composition, and stirring uniformly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010287184.XA CN111297761A (en) | 2020-04-13 | 2020-04-13 | Whitening composition and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010287184.XA CN111297761A (en) | 2020-04-13 | 2020-04-13 | Whitening composition and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111297761A true CN111297761A (en) | 2020-06-19 |
Family
ID=71157525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010287184.XA Pending CN111297761A (en) | 2020-04-13 | 2020-04-13 | Whitening composition and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111297761A (en) |
Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004189644A (en) * | 2002-12-10 | 2004-07-08 | Kanebo Ltd | Cosmetic |
| JP2014088360A (en) * | 2012-10-02 | 2014-05-15 | Ito:Kk | Composition for external use |
| KR20150066807A (en) * | 2013-12-09 | 2015-06-17 | 주식회사 엘지생활건강 | Cosmetics compositions for skin whitening t |
| CN105596222A (en) * | 2016-01-25 | 2016-05-25 | 广东工业大学 | Preparation method of mask for accurate repair and care |
| CN105708759A (en) * | 2016-02-19 | 2016-06-29 | 武汉市农业科学技术研究院林业果树科学研究所 | Pure natural antioxidant whitening multi-effect face cream with peony seed oil and preparation method thereof |
| CN106420536A (en) * | 2016-11-25 | 2017-02-22 | 上海娇云日化有限公司 | Hydrated cream and preparation method thereof |
| CN107281032A (en) * | 2017-07-01 | 2017-10-24 | 马南行 | A kind of composition of whitening spot-removing and preparation method thereof |
| CN107684536A (en) * | 2017-10-23 | 2018-02-13 | 宇妥藏药股份有限公司 | A kind of whitening moisturizing face masque and preparation method thereof |
| CN108294973A (en) * | 2018-03-28 | 2018-07-20 | 高华星 | Body whitening crème |
| US20180207077A1 (en) * | 2017-01-26 | 2018-07-26 | L'oreal | Microemulsion compositions comprising polydatin and method of use |
| CN108379155A (en) * | 2018-04-20 | 2018-08-10 | 安徽怡人生物科技有限公司 | A kind of acne eliminating cream and preparation method thereof |
| CN109223633A (en) * | 2018-09-14 | 2019-01-18 | 孟祥文 | A kind of eye-care frost and preparation method thereof |
| CN110200888A (en) * | 2019-06-28 | 2019-09-06 | 南京林业大学 | A kind of plant facial treatment mask of without essence and preparation method thereof |
-
2020
- 2020-04-13 CN CN202010287184.XA patent/CN111297761A/en active Pending
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004189644A (en) * | 2002-12-10 | 2004-07-08 | Kanebo Ltd | Cosmetic |
| JP2014088360A (en) * | 2012-10-02 | 2014-05-15 | Ito:Kk | Composition for external use |
| KR20150066807A (en) * | 2013-12-09 | 2015-06-17 | 주식회사 엘지생활건강 | Cosmetics compositions for skin whitening t |
| CN105596222A (en) * | 2016-01-25 | 2016-05-25 | 广东工业大学 | Preparation method of mask for accurate repair and care |
| CN105708759A (en) * | 2016-02-19 | 2016-06-29 | 武汉市农业科学技术研究院林业果树科学研究所 | Pure natural antioxidant whitening multi-effect face cream with peony seed oil and preparation method thereof |
| CN106420536A (en) * | 2016-11-25 | 2017-02-22 | 上海娇云日化有限公司 | Hydrated cream and preparation method thereof |
| US20180207077A1 (en) * | 2017-01-26 | 2018-07-26 | L'oreal | Microemulsion compositions comprising polydatin and method of use |
| CN107281032A (en) * | 2017-07-01 | 2017-10-24 | 马南行 | A kind of composition of whitening spot-removing and preparation method thereof |
| CN107684536A (en) * | 2017-10-23 | 2018-02-13 | 宇妥藏药股份有限公司 | A kind of whitening moisturizing face masque and preparation method thereof |
| CN108294973A (en) * | 2018-03-28 | 2018-07-20 | 高华星 | Body whitening crème |
| CN108379155A (en) * | 2018-04-20 | 2018-08-10 | 安徽怡人生物科技有限公司 | A kind of acne eliminating cream and preparation method thereof |
| CN109223633A (en) * | 2018-09-14 | 2019-01-18 | 孟祥文 | A kind of eye-care frost and preparation method thereof |
| CN110200888A (en) * | 2019-06-28 | 2019-09-06 | 南京林业大学 | A kind of plant facial treatment mask of without essence and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 王建新: "《化妆品植物原料大全》", 30 June 2012, 中国纺织出版社, pages: 140 * |
| 珠曼: "珠曼护肤系列之--赋活精华液", pages 4, Retrieved from the Internet <URL:https://mp.weixin.qq.com/s?src=11×tamp=1705457822&ver=5023&signature=05-3tt*bfca7pRXy5QEu-TsE-D9cf2cDqdvQtV661KlYXVnjFtmZ3iOVhyooBczsd0oa0TW2GXRJFvKhBJgQo8xNA8pFcDjafz21jpWiqeEF1TUCQSyuMqgkHvgwpZ3N&new=1> * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10463605B2 (en) | Camellia extract, its preparation method, and its use | |
| CN1838935B (en) | Agent for eliminating singlet oxygen and composition using the same | |
| CN110339076B (en) | Sun-screening composition with broad-spectrum light protection effect and preparation method and application thereof | |
| JP2019502745A (en) | A composition that brightens the skin, provides protection from sunlight and enables vitamin D production | |
| CN105560127B (en) | A kind of natural pigment CC frosts and preparation method thereof | |
| CN102228419A (en) | Emulsified sunscreen cosmetic | |
| US20230075953A1 (en) | Gadusol-containing sunscreen formulations | |
| CN108904316A (en) | Natural whiting antioxidant composition and nanogel cosmetics prepared therefrom | |
| CN112263496A (en) | Whitening agent, whitening oil gel containing whitening agent and preparation method of whitening oil gel | |
| KR100521768B1 (en) | Cosmetic Compositions for a Skin Whitening | |
| JP4530832B2 (en) | Skin external preparation for whitening, whitening agent, whitening method, and method for producing skin external preparation for whitening | |
| CN108938508A (en) | A kind of fig fruit extract and application thereof with sun-proof synergistic effect | |
| CN110292543A (en) | It is a kind of substitute ultraviolet absorbing agent biological composition and its application | |
| CN109394640A (en) | A kind of ferment skin care compositions and its application | |
| CN111991337B (en) | Composition with whitening, spot-lightening and antioxidant effects and preparation method and application thereof | |
| CN111012713B (en) | Whitening composition and preparation method and application thereof | |
| KR101050237B1 (en) | Functional Cosmetic Composition Using Pine Bark Extract | |
| CN111297761A (en) | Whitening composition and preparation method and application thereof | |
| US20100166683A1 (en) | Composition of external preparation for uv-protection comprising rehmannia glutinosa extracts | |
| JPH0578230A (en) | Skin-beautifying cosmetic | |
| JPH0812560A (en) | Skin external preparation | |
| CN115400067A (en) | Skin whitening composition | |
| CN113520902A (en) | Whitening emulsion and preparation method thereof | |
| CN111297762A (en) | Eye cream and preparation method thereof | |
| CN113520927A (en) | Skin care lotion with whitening effect and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20240208 Address after: Room A2-06-05, Building 1, No. 338 Huilongguan East Street, Changping District, Beijing, 100194 Applicant after: BEIJING GUOJI ZHONGFANG TRADITIONAL CHINESE MEDICINE Research Institute Country or region after: China Address before: 1105-2, floor 10, building a, yard 72, North West Third Ring Road, Haidian District, Beijing 100048 Applicant before: Beijing youyue Baishi Technology Development Co.,Ltd. Country or region before: China |
|
| TA01 | Transfer of patent application right |